Etcamah's Sept 4 Approval Does Not Rewrite Orserdu PAs or ODAC's ctDNA Dispute

On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (abemaciclib, palbociclib, or ribociclib) for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose tumors harbor an ESR1 mutation detected during first-line aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, as determined by an FDA-authorized companion diagnostic.[1] Concurrently, the agency approved the Guardant360 CDx liquid biopsy assay as the companion diagnostic to identify eligible patients harboring ESR1 mutations in circulating tumor DNA (ctDNA).[1]

This regulatory milestone establishes a biological and operational first in medical oncology: the first FDA approval of an anti-cancer regimen guided by the emergence of a molecular resistance mutation in liquid biopsy before standard radiographic or clinical disease progression occurs.[2] Yet for cancer center pharmacy and therapeutics (P&T) committees, health plan medical directors, and specialty pharmacy network managers, FDA's September 4 accelerated approval immediately intersects with established market structures, clinical trial controversies, and restrictive payer criteria:

FDA granted accelerated approval to camizestrant (Etcamah) on September 4, 2026 for HR-positive HER2-negative advanced breast cancer when an ESR1 mutation is detected during aromatase-inhibitor plus CDK4/6 inhibitor therapy. Can a plan treat that action, the SERENA-6 16-versus-9.2-month PFS, Guardant360, or EU authorization as a rewrite of Orserdu or Veppanu progression-gated prior authorization, as serial ctDNA monitoring coverage, or as a new preferred CDK4/6 partner?

The direct operational answers across regulatory, clinical, diagnostic, and market access dimensions are concrete and immediate:

Accelerated approval is a regulatory determination, not an automated payer policy rewrite: FDA granted accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act based on progression-free survival (PFS) measured from the initial detection of an ESR1 mutation in blood ctDNA, not from baseline randomization or traditional radiographic progression.[1] As of September 5, 2026, a live query of the Drugs@FDA API (last updated September 4, 2026) returns zero applications matching camizestrant, Etcamah, or New Drug Application (NDA) number 220359.[10] DailyMed's Structured Product Labeling (SPL) service returns zero records for etcamah, and FDA's Novel Drug Approvals for 2026 repository stops at Zanvastro (NME 37, approved September 3). That lag is a snapshot, not a finding that the oncology-approval page is unofficial; it still means commercial health plans and pharmacy benefit managers (PBMs) operate without a published federal package insert or final postmarketing requirement (PMR) schedule on day one.
ODAC voted 3 to 6 against clinically meaningful benefit prior to radiographic progression: On April 30, 2026, FDA's Oncologic Drugs Advisory Committee (ODAC) convened to evaluate NDA 220359. The committee voted 3 Yes, 6 No, and 0 Abstain on whether SERENA-6 demonstrated clinically meaningful benefit for camizestrant when an ESR1 mutation is detected on aromatase-inhibitor plus CDK4/6 inhibitor treatment prior to radiographic progression.[3][4] Members who voted no emphasized that overall survival (OS) benefit had not been demonstrated and that OS is a critical endpoint for changing the current treatment paradigm; they also said the trial did not adequately answer whether treating earlier based on a mutation is better than waiting for standard clinical or radiographic progression.[4]
FDA's approval text explicitly reaffirms the residual clinical uncertainty: While FDA exercised its statutory authority under the accelerated approval pathway to grant marketing authorization, the agency's official press release issued September 4 quotes Oncology Center of Excellence (OCE) Director Angelo de Claro that the action "marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing. But additional evidence is needed to confirm clinical benefit."[2] The same announcement states that confirmatory studies are required because it is not yet confirmed whether intervening at mutation detection, rather than at confirmed disease progression, translates into a clinically meaningful benefit.[2]
SERENA-6 PFS data represent an accelerated surrogate, not an overall survival victory: In the pivotal Phase 3 SERENA-6 trial (NCT04964934; n=315 randomized 1:1), investigator-assessed median PFS was 16 months (95% CI: 12.7–18.2) in the camizestrant plus CDK4/6 inhibitor arm versus 9.2 months (95% CI: 7.2–9.5) in the continuing AI plus CDK4/6 inhibitor arm (hazard ratio [HR] 0.44; 95% CI: 0.31–0.60; p < 0.00001).[1][7] Overall survival was not mature at the PFS cutoff.[1] AstraZeneca's U.S. press release cites a later pre-planned analysis of time to second progression or death (PFS2) of 25.7 versus 19.1 months (HR 0.63; 95% CI: 0.46–0.86); FDA's oncology-approval HTML does not use that PFS2 table as the statutory approval basis.[1][11]
Incumbent ESR1 oral therapies remain strictly progression-gated: Live federal labeling for both approved oral endocrine comparators—Stemline/Menarini's Orserdu (elacestrant; NDA 217639; SPL setid aa66ae5c-2bd2-4444-8178-b55651e054ef, effective_time 20260624, version 9) and Rigel's PROTAC Veppanu (vepdegestrant; NDA 219835; originated by Arvinas/Pfizer; SPL setid 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20, effective_time 20260612, version 1)—confirms that their indications require disease progression following at least one line of endocrine therapy.[5][6] Neither drug is approved for pre-progression molecular switching, and both are labeled as monotherapy rather than in combination with CDK4/6 inhibitors. Drugs@FDA records Veppanu's original approval as May 1, 2026 (standard review, Type 1 NME), not as accelerated approval.
Commercial and FEP Blue prior authorizations mandate objective disease progression: Current health plan coverage criteria for Orserdu enforce strict progression gates. Federal Employee Program (FEP) Blue Policy 5.21.202 (Orserdu, effective April 1, 2026) requires confirmed ESR1 mutation in plasma and explicit documentation of "disease progression following at least one line of endocrine therapy."[8] UnitedHealthcare Policy 2026 P 1407-4 (Orserdu, effective June 1, 2026) similarly mandates that "disease has progressed following at least one line of endocrine therapy."[9] Those product-named PDFs do not authorize Etcamah, and they still fail a pre-progression Orserdu request. They are not, by themselves, an Etcamah adjudication algorithm.
Continuing the CDK4/6 inhibitor creates a payer combination mismatch: FDA's approved indication instructs clinicians to continue the patient's existing CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) at the same dosage as when the ESR1 mutation was detected.[1] Yet existing CDK4/6 policies, such as FEP Blue Policy 5.21.054 (Ibrance, effective April 1, 2026), authorize palbociclib with an aromatase inhibitor or fulvestrant (or inavolisib plus fulvestrant if PIK3CA) and require documentation of no disease progression for renewal.[14] Substituting camizestrant for letrozole or anastrozole while renewing palbociclib is not a combination listed in that PDF.
Companion diagnostic approval does not mandate serial ctDNA surveillance coverage: FDA's approval of Guardant360 CDx as the companion diagnostic for Etcamah establishes analytical and clinical validity for patient selection.[1] Guardant360 CDx previously secured ESR1 companion diagnostic indications for Orserdu in January 2023 and for Veppanu under PMA supplement P200010/S025 on May 1, 2026.[13] That CDx sentence identifies eligible patients; it does not, by itself, write coverage for the every-two-to-three-month surveillance schedule used in SERENA-6 at the time of routine scans.[7][11] Public Orserdu and Ibrance PAs reviewed here ask for an ESR1 result, not a monitoring cadence.[8][9][14]

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│               ORAL ESR1 BREAST CANCER THERAPIES: REGULATORY & ACCESS SCORECARD                          │
├──────────────────────────┬──────────────────────────┬──────────────────────────┬───────────────────────┤
│ Dimension                │ Etcamah (camizestrant)   │ Orserdu (elacestrant)    │ Veppanu (vepdegestrant│
├──────────────────────────┼──────────────────────────┼──────────────────────────┼───────────────────────┤
│ Sponsor / NDA            │ AstraZeneca / NDA 220359 │ Stemline / NDA 217639    │ Rigel / NDA 219835    │
│ FDA Approval Date        │ Sept 4, 2026             │ Jan 27, 2023             │ May 1, 2026           │
│ Regulatory Status        │ Accelerated Approval     │ Traditional Approval     │ Traditional Approval  │
│ Review Pathway           │ Standard, Breakthrough   │ Priority Review          │ Standard Review       │
│ Indication Line / Timing │ Emergent ESR1 during 1L  │ Post-progression (>=1L)  │ Post-progression (>=1L│
│ Radiographic Progression │ NOT required (pre-prog)  │ Required in label        │ Required in label     │
│ Companion Regimen        │ + CDK4/6 inhibitor       │ Monotherapy              │ Monotherapy (PROTAC)  │
│ Registered Pivotal Trial │ SERENA-6 (NCT04964934)   │ EMERALD (NCT03778931)    │ VERITAC-2 (NCT05654623│
│ Pivotal Population (n)   │ n=315 randomized 1:1     │ n=478 (n=228 ESR1-mut)   │ n=624 (n=270 ESR1-mut)│
│ Primary Efficacy Result  │ Median PFS 16 vs 9.2 mo  │ Median PFS 3.8 vs 1.9 mo │ Median PFS 5.0 vs 2.1 │
│ Hazard Ratio (95% CI)    │ HR 0.44 (0.31–0.60)      │ HR 0.55 (0.39–0.77)      │ HR 0.57 (0.42–0.77)   │
│ Overall Survival Status  │ Immature at PFS analysis │ NS (HR 0.90; 0.63–1.30)  │ Immature (16% deaths) │
│ FDA Advisory Committee   │ ODAC 04/30/2026 (3Y / 6N)│ Not convened             │ Not convened          │
│ Companion Diagnostic     │ Guardant360 CDx          │ Guardant360 CDx (2023)   │ Guardant360 (P200010/ │
│ Labeled Boxed Warning    │ Arrhythmia / QTc prolong.│ None                     │ None                  │
│ Labeled Key Warnings     │ Bradycardia, Embryo-fetal│ Dyslipidemia, embryo-fet.│ QTc, embryo-fetal tox │
│ Orange Book TE Code      │ Pending listing          │ BLANK (Single-source RLD)│ BLANK (Single-source) │
│ Medicaid NADAC 2026 Data │ 0 rows (Specialty Rx)    │ 0 rows (Specialty Rx)    │ 0 rows (Specialty Rx) │
│ FEP Policy Progression   │ Not listed on 5.21.202   │ Mandates progression     │ Mandates progression  │
└──────────────────────────┴──────────────────────────┴──────────────────────────┴───────────────────────┘

Cross-trial PFS is not a ranking: SERENA-6, EMERALD, and VERITAC-2 enrolled different lines of therapy, combination versus monotherapy regimens, and primary-analysis populations. The table is a labeled-use map, not a preferred-product score.

What Did FDA Approve on September 4 Versus What Drugs@FDA, DailyMed, and the 2026 NME Table Still Show on September 5?

On September 4, 2026, FDA's Center for Drug Evaluation and Research (CDER) published an accelerated approval notice for camizestrant (Etcamah tablets, AstraZeneca) on its official Oncology (Cancer) Approved Drugs portal.[1] However, market access teams navigating the immediate 24-hour aftermath must distinguish between an agency web notice and the formal integration of an approved product into federal regulatory databases.

The Scope of the September 4 Labeled Indication

According to FDA's official approval determination, camizestrant is indicated:

"in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer whose tumors have an estrogen receptor 1 (ESR1) mutation detected during aromatase inhibitor and CDK4/6 inhibitor therapy, as determined by an FDA-authorized test."[1]

Key elements embedded within FDA's regulatory action include:

Specific Clinical Setting: Patients must have received initial endocrine-based therapy comprising an aromatase inhibitor (anastrozole or letrozole) in combination with a CDK4/6 inhibitor for a minimum of six months without investigator-assessed disease progression prior to ESR1 detection.[1][7]
Continued CDK4/6 Dosing: Clinicians are directed to continue the same CDK4/6 inhibitor at the same dosage being administered when the ESR1 mutation was identified.[1]
Accelerated Approval Basis: Approval is granted under 21 CFR Part 314 Subpart H based on progression-free survival measured from the time of ESR1 mutation detection. Continued approval remains contingent upon verification and description of clinical benefit in confirmatory clinical trials.[1]
Boxed Warning for Arrhythmia: The label includes a Boxed Warning regarding the risk of arrhythmia due to QTc interval prolongation when co-administered with other QTc-prolonging medicinal products.[1]
Warnings and Precautions: Labeled warnings include bradycardia and embryo-fetal toxicity.[1]
Regulatory Mechanisms: The review was conducted under Project Orbis in collaboration with international regulatory authorities—including the Australian Therapeutic Goods Administration (TGA), Brazil's ANVISA, Health Canada, Singapore's Health Sciences Authority (HSA), and Swissmedic. The application received Breakthrough Therapy designation and was reviewed under standard review timelines.[1]

Federal Database Lag on September 5: Auditing the Public Record

While the oncology approval page and press release were published on September 4, federal drug repositories routinely exhibit administrative latency:

Drugs@FDA Query: As of September 5, 2026, live automated calls to https://api.fda.gov/drug/drugsfda.json (database last updated September 4, 2026) return zero matching records for camizestrant, openfda.brand_name:"ETCAMAH", or application_number:NDA220359.[10] The FDA approval announcement explicitly notes: "Full prescribing information will be posted on Drugs@FDA."[1]
DailyMed Structured Product Labeling: A live query of the National Library of Medicine (NLM) DailyMed API (https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=etcamah; database snapshot September 4, 2026, 07:43:12 PM EST) returns zero SPL elements.
Novel Drug Approvals for 2026: FDA CDER's Novel Drug Approvals calendar lists 37 novel chemical entities approved year-to-date through September 3, 2026, concluding with Zanvastro (zilganersen; NME 37). Etcamah has not yet been assigned an NME tracking sequence.
Medicaid NADAC 2026 Files: Direct queries against the Centers for Medicare & Medicaid Services (CMS) Medicaid National Average Drug Acquisition Cost (NADAC) 2026 datastore return zero pricing rows for ETCAMAH, CAMIZESTRANT, ORSERDU, ELACESTRANT, VEPPANU, or VEPDEGESTRANT. This absence does not imply a zero-dollar cost; rather, it reflects that oral targeted oncolytics are distributed through closed specialty pharmacy channels rather than retail community pharmacies surveyed by NADAC.

For managed care pharmacy directors, this regulatory gap means that formal national drug codes (NDCs), package configurations, and final postmarketing commitments cannot be officially imported into core claim adjudication engines until the SPL is published.

Why Did ODAC Vote 3 to 6 Against Clinically Meaningful Benefit for Switching Before Radiographic Progression, and What Confirmatory Sentence Did FDA Still Publish at Approval?

The central controversy surrounding camizestrant's accelerated approval lies in the split between FDA's advisory committee and the agency's final regulatory action. Understanding this divergence is essential for P&T committees weighing whether to place Etcamah on formulary ahead of confirmatory evidence.

The April 30, 2026 ODAC Meeting: Evaluating NDA 220359

On April 30, 2026, FDA convened the Oncologic Drugs Advisory Committee to review NDA 220359 (camizestrant tablets, AstraZeneca).[3] The committee's morning session focused exclusively on the proposed indication: initiating camizestrant upon emergence of an ESR1 mutation during first-line endocrine therapy prior to radiographic progression.[3]

According to the final summary minutes of the ODAC meeting, approved on May 26, 2026, the morning voting question was:

"Based on the results of SERENA-6, has clinically meaningful benefit for camizestrant been demonstrated for the treatment of patients with HR+/HER2- metastatic breast cancer with a tumor ESR1 mutation detected while on aromatase inhibitor and CDK4/6 inhibitor treatment, prior to radiographic progression?"[4]

The final vote was:

Yes: 3
No: 6
Abstain: 0

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│             ODAC APRIL 30, 2026 VOTE BREAKDOWN: NDA 220359 (CAMIZESTRANT TABLETS)                       │
├──────────────────────────┬───────┬─────────────────────────────────────────────────────────────────────┤
│ Voting Position          │ Count │ Primary Committee Rationale Documented in Summary Minutes          │
├──────────────────────────┼───────┼─────────────────────────────────────────────────────────────────────┤
│ YES (Clinically Meaning- │   3   │ • Delay in disease progression, with supportive signals in other    │
│     ful Benefit Shown)   │       │   endpoints and no detriment to overall survival                    │
│                          │       │ • Could postpone more toxic therapies such as chemotherapy          │
│                          │       │ • ctDNA to identify resistance earlier as a field advance           │
├──────────────────────────┼───────┼─────────────────────────────────────────────────────────────────────┤
│ NO (Clinically Meaning-  │   6   │ • No demonstrated OS benefit; OS is critical for a paradigm change  │
│     ful Benefit NOT Shown│       │ • Did not show treating earlier on a mutation beats waiting for     │
│                          │       │   standard clinical or radiographic progression                     │
│                          │       │ • How and when patients were tested made results hard to interpret  │
│                          │       │ • Post-progression treatment differences; biomarker not proven to   │
│                          │       │   predict clinical benefit; PROs not indicative of clinical benefit │
├──────────────────────────┼───────┼─────────────────────────────────────────────────────────────────────┤
│ ABSTAIN                  │   0   │ No voting members abstained.                                        │
└──────────────────────────┴───────┴─────────────────────────────────────────────────────────────────────┘

The Committee's Core Methodological Criticisms

The six voting members who rejected the clinical meaningfulness of the SERENA-6 data articulated several objections documented in the official minutes:[4]

Overall survival as the paradigm-change endpoint: Members who voted no emphasized that there was no demonstrated overall survival benefit and felt that overall survival is a critical endpoint for changing the current treatment paradigm. At the primary PFS data cutoff, FDA's oncology-approval page likewise states that OS data were not mature.[1][4]
Sequencing versus early intervention: Members also stated that the trial did not adequately answer the central question of whether treating earlier based on a mutation is better than waiting for standard clinical or radiographic progression. SERENA-6 compared camizestrant plus CDK4/6 against continued AI plus CDK4/6. Standard practice does not continue an ineffective AI indefinitely; once radiographic progression occurs, patients are routinely switched to second-line therapies, such as fulvestrant, elacestrant (Orserdu), or vepdegestrant (Veppanu).
Testing timing and post-progression differences: Some members said the results were difficult to interpret because of how and when patients were tested, while others raised concerns about trial design, including differences in treatment after progression and the fact that intervening when the biomarker was detected has not yet been proven to predict clinical benefit. Members also shared concerns about the quality of the patient-reported outcomes information and stated that this information was not indicative of clinical benefit.[4]

FDA's Confirmatory Study Mandate at Approval

Despite ODAC's 3-to-6 negative vote, FDA elected to grant accelerated approval under its statutory authority. However, the agency's September 4 press release clearly reflects the committee's documented concerns:

"Accelerated approval was based on how long patients lived without the disease worsening, measured from the point when the resistance mutation was first detected in the blood. Confirmatory studies are required because it is not yet confirmed whether intervening at that point, rather than at confirmed disease progression, translates into a clinically meaningful benefit."[2]

Furthermore, while AstraZeneca's U.S. press release highlighted a later pre-planned PFS2 analysis (25.7 months for camizestrant vs 19.1 months for continued AI; HR 0.63; 95% CI 0.46–0.86),[11] FDA's official oncology approval document strictly bases accelerated approval on the primary investigator-assessed PFS of 16 versus 9.2 months and reiterates that overall survival remains immature.[1]

This explicit regulatory language gives commercial payers documented residual uncertainty to work with: product-named PAs still have to be written, and existing Orserdu/Veppanu progression gates do not automatically become Etcamah criteria. It does not convert an FDA-approved product into an investigational drug, and it does not require a plan to deny coverage.

Do Live Orserdu and Veppanu Labels, and FEP 5.21.202 and UHC 2026 P 1407-4, Still Require Disease Progression After Endocrine Therapy?

Oncology practices may assume that because Etcamah targets the same ESR1 point mutations as elacestrant and vepdegestrant, health plans will treat these oral endocrine agents as clinically interchangeable. A live-label and public-PA audit shows why that assumption fails: progression gating.

Federal Labeling Comparison: Indication Scopes

Direct inspection of active FDA Structured Product Labeling demonstrates that Orserdu and Veppanu are approved exclusively as post-progression therapies:

Orserdu (elacestrant; NDA 217639): Approved under traditional approval in January 2023. The live SPL (setid aa66ae5c-2bd2-4444-8178-b55651e054ef, effective_time 20260624, version 9) states in Section 1:

"ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy."[5]
Veppanu (vepdegestrant; NDA 219835): Approved May 1, 2026, as an oral PROTAC estrogen receptor degrader (Drugs@FDA original approval, standard review, Type 1 NME). The live SPL (setid 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20, effective_time 20260612, version 1) states in Section 1:

"VEPPANU is indicated for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy."[6]

Neither Orserdu nor Veppanu contains labeled indications for use prior to objective disease progression, nor are they approved for co-administration with CDK4/6 inhibitors. Clinically, attempting to use elacestrant or vepdegestrant upon ctDNA mutation detection without radiographic progression constitutes an off-label application unsupported by pivotal trial evidence.

Commercial Payer Policy Analysis: The Progression Criterion

Health plan prior authorization criteria for oral ESR1 antagonists are explicitly structured around labeled post-progression failure. Two representative national payer policies illustrate this enforcement:

1. FEP Blue Pharmacy Policy 5.21.202 (Orserdu)

The Federal Employee Program Blue Cross Blue Shield policy for Orserdu (last reviewed March 6, 2026; effective April 1, 2026) requires all of the following for initial approval:[8]

Age 18 years or older; female patients must be postmenopausal.
Advanced or metastatic ER-positive, HER2-negative breast cancer.
Presence of an ESR1 mutation in a plasma specimen using an FDA-approved test.
Disease progression following at least one line of endocrine therapy.

Under those written criteria, a prior authorization request submitted for a patient whose scans show stable disease—even with rising ESR1 variant allele frequency in plasma ctDNA—fails the progression requirement. That is a checkable Orserdu-policy failure, not a published Etcamah denial rule.

2. UnitedHealthcare Pharmacy Clinical Program 2026 P 1407-4 (Orserdu)

UnitedHealthcare's commercial prior authorization criteria for Orserdu (effective June 1, 2026) enforce identical clinical boundaries:[9]

Coverage requires that the patient has advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation, AND
"Disease has progressed following at least one line of endocrine therapy."

While UnitedHealthcare provides an administrative pathway for National Comprehensive Cancer Network (NCCN) Compendium Category 1, 2A, or 2B recommendations, that escape applies only if NCCN actually lists the use. Until NCCN updates Breast Cancer guidelines with a pre-progression camizestrant row, the product-named Orserdu PDF still requires progression after endocrine therapy. That is a snapshot of two public PAs, not a finding that every plan must deny Etcamah.

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                PRIOR AUTHORIZATION ADJUDICATION DECISION TREE: ESR1 AGENTS                             │
├──────────────────────────────────────┬─────────────────────────────────────────────────────────────────┤
│ Clinical Scenario                    │ Payer Adjudication Outcome & Policy Basis                       │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ ctDNA ESR1 mutation detected,        │ • Etcamah: No product-named PA found on the current PA SERP;   │
│ radiographic scans show STABLE       │   FDA HTML is pre-progression with continued CDK4/6.           │
│ disease on 1L AI + CDK4/6            │ • Orserdu: Fails FEP 5.21.202 / UHC P 1407-4 progression gate. │
│                                      │ • Veppanu: Live SPL still requires progression after ET.       │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ Radiographic PROGRESSION documented, │ • Orserdu: Can meet FEP 5.21.202 if other listed fields match. │
│ ctDNA confirms ESR1 mutation         │ • Veppanu: Matches live post-progression SPL; no Veppanu PA    │
│                                      │   PDF is cited on this page.                                   │
│                                      │ • Etcamah: Labeled with continued CDK4/6, not as monotherapy   │
│                                      │   salvage; SERENA-6 switched during first-line maintenance.    │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ ESR1 mutation detected in tissue     │ • Orserdu / Veppanu: Guardant360 plasma CDx or other           │
│ biopsy, no plasma ctDNA test         │   FDA-authorized testing as the labeled test language allows.  │
│ performed                            │ • Etcamah: Indication is an FDA-authorized test; SERENA-6 and  │
│                                      │   Guardant360 CDx used blood ctDNA. Tissue-only workflows     │
│                                      │   still need a posted USPI CDx sentence, which is not live.   │
└──────────────────────────────────────┴─────────────────────────────────────────────────────────────────┘

Does Continuing the Same CDK4/6 at the Same Dose Rewrite FEP 5.21.054 Ibrance Combination-With-AI Language or Write Serial ctDNA Monitoring Into CDK4/6 PAs?

A critical operational complexity introduced by Etcamah's approval is its required combination partner. Unlike Orserdu or Veppanu, which are administered as single-agent monotherapies, camizestrant is approved strictly in combination with a CDK4/6 inhibitor.[1]

The Combination Mandate and Payer Friction

FDA's approval text states:

"Continue the CDK4/6 inhibitor at the same dosage as when the ESR1 mutation was detected."[1]

This directive creates immediate administrative and contracting challenges across commercial health plans:

Restrictive Endocrine Combination Policies: Existing payer policies governing CDK4/6 inhibitors specify permissible combination partners. For example, FEP Blue Policy 5.21.054 (Ibrance/palbociclib; effective April 1, 2026) authorizes coverage under specific labeled paradigms:[14]
- Initial endocrine-based therapy in combination with an aromatase inhibitor.
- Second-line therapy in combination with fulvestrant following disease progression.
- Combination with inavolisib plus fulvestrant for PIK3CA-mutated disease.
Policy 5.21.054 contains zero language authorizing palbociclib in combination with camizestrant. When a physician submits a prescription renewal for palbociclib indicating that the partner drug is now Etcamah rather than letrozole or anastrozole, combination-partner edits can fail even if the CDK4/6 inhibitor itself remains on formulary.
Renewal Criteria and Progression Free Status: CDK4/6 renewal criteria, including FEP Blue 5.21.054, require confirmation that the patient has experienced "no disease progression." While patients switching to Etcamah in SERENA-6 did not have radiographic progression, payer review nurses reviewing medical records may interpret the detection of an emergent ESR1 resistance mutation as evidence of therapeutic failure on the first-line regimen, leading to potential denial of the continued CDK4/6 inhibitor.
Dual oral specialty pharmacy cost-sharing: Co-administering two branded oral oncolytics (camizestrant plus a CDK4/6 inhibitor) puts two specialty pharmacy claims on the same cycle. Public NADAC files still return zero rows for these products, so this page does not invent coinsurance percentages or WAC. The operational point is dual specialty adjudication, not a priced total-cost model.

Does Guardant360's Existing Orserdu and Veppanu ESR1 Claim Automatically Become a Longitudinal Monitoring Benefit for a Third Product?

Concurrent with Etcamah's approval, FDA approved Guardant Health's Guardant360 CDx assay as a companion diagnostic to detect ESR1 mutations for patient selection.[1] While diagnostic manufacturers frequently market such approvals as validation of longitudinal molecular monitoring, managed care coverage policies operate under entirely distinct evidence thresholds.

Diagnostic Lineage: Companion Diagnostic vs. Serial Surveillance

Guardant360 CDx holds an established regulatory history in breast cancer companion diagnostics:

January 2023: Approved as the companion diagnostic for Orserdu (elacestrant) to detect ESR1 missense mutations in plasma ctDNA following endocrine progression.[5]
May 1, 2026: Approved under Premarket Approval (PMA) supplement P200010/S025 as the companion diagnostic for Veppanu (vepdegestrant) for post-progression ESR1 detection.[13]
September 4, 2026: Approved as the companion diagnostic for Etcamah (camizestrant) upon emergence during first-line therapy.[1]

However, an FDA companion diagnostic clearance establishes clinical validity—confirming that the assay accurately identifies the genomic alterations that define the eligible trial population. It does not establish clinical utility or mandate health plan coverage for repetitive, serial testing.

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│            GUARDANT360 CDX: REGULATORY CDX STATUS VS. COMMERCIAL PAYER COVERAGE                        │
├──────────────────────────┬──────────────────────────┬──────────────────────────────────────────────────┤
│ Diagnostic Dimension     │ FDA Companion Diagnostic │ What the cited public PAs actually say           │
├──────────────────────────┼──────────────────────────┼──────────────────────────────────────────────────┤
│ Regulatory Authorization │ PMA P200010; S025 5/1/26 │ No Etcamah PA PDF on the current PA SERP          │
│ Diagnostic Intent        │ Patient selection CDx    │ Orserdu PAs ask for an ESR1 result               │
│ Serial ctDNA Monitoring  │ SERENA-6 used q2–3m      │ Not a field in FEP 5.21.202, UHC P 1407-4, or    │
│ at routine scans         │ scans (sponsor/trial)    │ FEP 5.21.054                                     │
│ Coverage implication     │ CDx validity ≠ benefit   │ Do not treat Guardant marketing as a paid serial │
│                          │                          │ monitoring benefit                                │
└──────────────────────────┴──────────────────────────┴──────────────────────────────────────────────────┘

The Longitudinal ctDNA Reimbursement Hurdle

In SERENA-6, ESR1 status was assessed by blood ctDNA using Guardant360 CDx during first-line AI plus CDK4/6 therapy; AstraZeneca's trial communications describe monitoring at the time of routine scans every two to three months.[7][11] Implementing that protocol in clinic is a coverage question separate from the one-time CDx association FDA posted on September 4.

Current public PAs reviewed for this page do not answer that question:

No monitoring field in the cited drug PAs: FEP 5.21.202, UHC 2026 P 1407-4, and FEP 5.21.054 require an ESR1 result or a CDK4/6 combination partner; they do not list a serial ctDNA cadence.[8][9][14]
Denial-cascade risk remains the CDx-then-drug sequencing problem: If a plan treats surveillance liquid biopsy as investigational, a missing covered companion-diagnostic report can still block the drug PA under companion diagnostic prior authorization sequencing. That is a workflow risk, not a finding that every MolDX contractor has already published an Etcamah-specific LCD.
P&T diagnostic budgeting: Health systems that stand up send-out surveillance still need a covered use. This page does not invent a CPT, PLA, or Medicare frequency limit for that use.

Which Existing PharmaDossier Pages Own Veppanu ESR1 Access, CDK4/6 Payer Mismatch, CDx PMA Supplements, CDx-Denial Workflows, and Boxed-Warning-Versus-PA Clocks, and Must Not Be Rewritten Here?

To preserve strict editorial boundaries and prevent cross-topic cannibalization across PharmaDossier's regulatory and market access portfolio, this analysis links to and builds upon existing baseline analyses without duplicating their specialized content:

Post-Progression ESR1 Degraders: For a detailed breakdown of oral PROTAC pharmacology, the Phase 3 VERITAC-2 trial design, and second-line monotherapy access dynamics, refer to our foundational analysis of Veppanu post-progression ESR1 access.
CDK4/6 Class Utilization and First-Line Combinations: For comprehensive coverage of palbociclib, ribociclib, and abemaciclib payer tiering, step therapy protocols, and the June 2026 PATINA maintenance expansion into HER2-positive disease, consult our review of the CDK4/6 prior-authorization mismatch.
Companion Diagnostic Device Platforms and PMA Supplements: The complete historical census of FDA Premarket Approval supplements across FoundationOne CDx, Guardant360 CDx, and Therascreen platforms—including the 2023 elacestrant and May 2026 vepdegestrant expansions—is maintained in our audit of Guardant360 CDx PMA supplements.
Diagnostic Denials and Downstream Oncology Claims: The procedural mechanics of how liquid biopsy billing rejections trigger secondary denials in pharmacy benefit adjudication are analyzed in our operational guide to CDx-then-drug PA sequencing.
Biomarker-Driven Second-Line Options in HR+/HER2- Disease: For non-ESR1 genomic subsets, including PIK3CA wild-type disease and gedatolisib access following CDK4/6 progression, see our coverage of PIK3CA wild-type breast-cancer access.
Safety Labeling Updates and Formulary Latency: The regulatory principle that a boxed warning does not automatically rewrite product-named prior authorization criteria is documented in our study of how a boxed warning does not rewrite current PAs. Etcamah's QTc boxed warning is a labeling fact on FDA's oncology-approval HTML; it is not yet a field in the Orserdu or Ibrance PDFs cited here.
European Regulatory Harmonization: For analysis of European Medicines Agency (EMA) marketing authorizations—including Etcamah's July 20, 2026 European Commission approval (EMEA/H/C/006494)—and Health Technology Assessment (HTA) clinical efficacy reviews, refer to our explainer on EU joint clinical assessment.

Frequently Asked Questions

Is camizestrant FDA-approved today?

Yes. On September 4, 2026, the FDA granted accelerated approval to camizestrant (Etcamah, AstraZeneca) in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose tumors have an ESR1 mutation detected during aromatase inhibitor plus CDK4/6 inhibitor therapy.[1] However, as of September 5, 2026, federal database synchronization remains underway: Drugs@FDA API, DailyMed SPL records, and the 2026 NME calendar have not yet published the finalized digital package insert.[10]

Does accelerated approval based on PFS from ESR1 detection require a plan to cover Etcamah before imaging progression?

No. Accelerated approval grants marketing authorization, but it does not rewrite product-named prior authorization PDFs. Commercial plans, Medicare Part D sponsors, and Medicaid programs still have to write Etcamah-specific criteria. ODAC's 3-to-6 vote is documented residual uncertainty, not a coverage mandate to deny an FDA-approved product or to restrict it to clinical-trial participants.[2][4]

Can a plan treat Etcamah as interchangeable with Orserdu or Veppanu because all three use Guardant360 for ESR1?

No. Etcamah, Orserdu (elacestrant), and Veppanu (vepdegestrant) occupy distinct clinical niches and labeled indications.[1][5][6] Orserdu and Veppanu are approved as single-agent monotherapies strictly for patients who have already experienced objective disease progression following endocrine therapy.[5][6] Etcamah is approved strictly as a pre-progression combination regimen that continues the patient's existing CDK4/6 inhibitor upon blood ctDNA mutation emergence.[1] Substituting one for another violates FDA labeling and existing prior authorization rules.

If ODAC voted no, does that mean a plan must deny Etcamah after FDA approval?

No. An advisory committee vote is non-binding guidance to the FDA. While six ODAC members voted that clinically meaningful benefit had not been demonstrated prior to radiographic progression, FDA exercised its statutory discretion to approve camizestrant under the accelerated approval framework based on the statistically significant 16 versus 9.2 month PFS benefit.[1][4] Payers are not legally mandated to deny the drug; P&T committees can weigh the 3-to-6 vote when writing utilization management, without treating the minutes as a coverage statute.

Sources

U.S. Food and Drug Administration (FDA). "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer." FDA Oncology (Cancer) / Approved Drugs, Content Current September 4, 2026. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative.

2. U.S. Food and Drug Administration (FDA). "FDA Grants Accelerated Approval to a New Breast Cancer Treatment." FDA News Release, Content Current September 4, 2026. Available at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment.

3. U.S. Food and Drug Administration (FDA). "April 30, 2026 Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement and Materials." FDA Advisory Committee Calendar, Meeting Date April 30, 2026. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-30-2026-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04302026.

4. U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). "Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting April 30, 2026." Approved May 26, 2026. Available at: https://www.fda.gov/media/192813/download.

5. U.S. National Library of Medicine (NLM) DailyMed. "ORSERDU (elacestrant hydrochloride) tablet, film coated." Stemline Therapeutics Inc., NDA 217639, SPL Set ID: aa66ae5c-2bd2-4444-8178-b55651e054ef, Effective Time: June 24, 2026, Version 9. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef.

6. U.S. National Library of Medicine (NLM) DailyMed. "VEPPANU (vepdegestrant) tablet, film coated." Rigel Pharmaceuticals, Inc., NDA 219835, SPL Set ID: 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20, Effective Time: June 12, 2026, Version 1. Drugs@FDA records original approval May 1, 2026 (ORIG-1 AP, standard review, Type 1 NME). Live SPL indications contain no accelerated-approval language. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20.

7. ClinicalTrials.gov. "Phase 3 Study of Camizestrant (AZD9833) Plus CDK4/6 Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer with Emergent ESR1 Mutation (SERENA-6)." National Institutes of Health (NIH), ClinicalTrials.gov Identifier: NCT04964934, Sponsor: AstraZeneca, Actual Enrollment: 315, Last Update: July 14, 2026. Available at: https://clinicaltrials.gov/study/NCT04964934.

8. Blue Cross Blue Shield Association (BCBSA) Federal Employee Program (FEP). "FEP Blue Pharmacy Policy 5.21.202 Orserdu (elacestrant)." CVS Caremark Clinical Documentation, Last Review March 6, 2026, Effective April 1, 2026. Available at: https://info.caremark.com/content/dam/enterprise/caremark/microsites/dig/pdfs/pa-fep/fep-criteria/FEP_Criteria_Orserdu.pdf.

9. UnitedHealthcare Pharmacy. "Clinical Pharmacy Programs 2026 P 1407-4 Orserdu (elacestrant) Prior Authorization/Notification." UnitedHealthcare Commercial Medical Policy, P&T Date March 2026, Effective June 1, 2026. Available at: https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/h-p/PA-Notification-Orserdu.pdf.

10. U.S. Food and Drug Administration (FDA). "Drugs@FDA Database and OpenFDA API Application Records." Inquiries for camizestrant, Etcamah, and NDA 220359, API Snapshot September 4, 2026. Available at: https://api.fda.gov/drug/drugsfda.json.

11. AstraZeneca Pharmaceuticals LP. "ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer." US Media Press Release, Published September 4, 2026. Available at: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/ETCAMAH-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-approved-in-the-US-for-1st-line-advanced-HR-positive-breast-cancer.html.

12. European Medicines Agency (EMA). "Etcamah (camizestrant) European Public Assessment Report (EPAR) Overview." EMA Committee for Medicinal Products for Human Use (CHMP), Marketing Authorisation Issued July 20, 2026, Procedure No. EMEA/H/C/006494. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/etcamah.

13. U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). "Premarket Approval (PMA) Database: Guardant360 CDx." PMA P200010 Supplement S025 (Decision Date May 1, 2026; vepdegestrant ESR1 CDx expansion). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010S025.

14. Blue Cross Blue Shield Association (BCBSA) Federal Employee Program (FEP). "FEP Blue Pharmacy Policy 5.21.054 Ibrance (palbociclib)." CVS Caremark Clinical Documentation, Last Review March 6, 2026, Effective April 1, 2026. Available at: https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/March/Pharmacy-Policies/Remove-and-Replace/521054-Ibrance-palbociclib.pdf.

15. AstraZeneca PLC. "US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data." Press Release, Published May 27, 2026. Available at: https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html.